Literature DB >> 10645558

The prevention of Dirofilaria repens infection with ivermectin/pyrantel chewables.

F Pollono1, M Pollmeier, L Rossi.   

Abstract

This trial was conducted to test the efficacy of ivermectin/pyrantel chewables in preventing the development of Dirofilaria repens in dogs. The trial included 155 dogs from an endemic area in North-Western Italy. Prior to enrollment in the study, none of the dogs had microfilariae of D. immitis or D. repens in a concentration test, and all dogs were also seronegative for adult heartworm antigen. Animals remained with their owners and were dosed six times, at monthly intervals according to body weight. Efficacy against D. repens was evaluated approximately 6 and 12 months after the first dosing. None of the treated dogs was found to harbour microfilariae of D. repens or D. immitis on either occasion, whereas 6 of 24 untreated controls had circulating D. repens microfilariae at the final testing. The treatment was well accepted by all dogs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10645558

Source DB:  PubMed          Journal:  Parassitologia        ISSN: 0048-2951


  2 in total

1.  Evaluation of the Adulticidal Efficacy of Imidacloprid 10 %/Moxidectin 2.5 % (w/v) Spot-on (Advocate®, Advantage® Multi) against Dirofilaria repens in Experimentally Infected Dogs.

Authors:  Gabriele Petry; Marco Genchi; Holger Schmidt; Roland Schaper; Bettina Lawrenz; Claudio Genchi
Journal:  Parasitol Res       Date:  2015-08       Impact factor: 2.289

2.  Field clinical study evaluating the efficacy and safety of an oral formulation containing milbemycin oxime/praziquantel (Milbemax®, Novartis Animal Health) in the chemoprevention of the zoonotic canine infection by Dirofilaria repens.

Authors:  Angela Di Cesare; Gabriele Braun; Emanuela Di Giulio; Barbara Paoletti; Vincenzo Aquilino; Roberto Bartolini; Francesco La Torre; Silvana Meloni; Jason Drake; Federico Pandolfi; Stefania Avolio; Donato Traversa
Journal:  Parasit Vectors       Date:  2014-07-29       Impact factor: 3.876

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.